Dapsone is an antibiotic medication used in multidrug regimens and approved by the United States Food and Drug Administration (FDA) for treating leprosy and dermatitis herpetiformis
2 A Cochrane review published in 2010 did not identify any randomized controlled trials evaluating dapsone as a therapy for BP
The concept that ES may be an integral manifestation of early pemphigus acantholysis was first introduced by Emmerson and Wilson-Jones 18 in 1968
Dapsone is a chemotherapeutic agent primarily used in treating leprosy, Pneumocystis jiroveci (previously carinii) pneumonia, and malaria
In MMP, autoantibodies are directed against Previous reports have explored different molecular targets for dapsone and provided insight into the anti-inflammatory mechanism of dapsone
According to the 2015 European Recommendations, the treatment of choice in BP are potent topical corticosteroids
Dermatologica
Regarding the mechanism of action, one can discriminate In three patients with "intolerance" to sulfapyridine, therapy was changed to dapsone because of nausea, vomiting, headache, or lack of efficacy over a 6-week to 6-month trial period
DB00250
Dapsone has been used successfully as adjuvant therapy for bullous pemphigoid (BP)
5 mg/kg per day) and Pemphigoid vegetans is a rare variant of bullous pemphigoid
Hence, further studies are needed to evaluate the efficacy of dapsone as a single agent in maintaining disease remission in patients with AMCBD
In this Bullous pemphigoid (BP) is the most common autoimmune subepidermal bullous disease
pemphigoid Rogers 1982 suggest that dapsone may be beneficial for the treatment of severe aphthous ulcers
Dapsone inhibits the folic acid pathway by preventing the bacteria from utilizing para-aminobenzoic acid (PABA) to synthesize folic acid by competitively antagonizing PABA
5mg/kg/day, up to 200mg/day
Call your doctor for medical advice about side effects
Bullous pemphigoid; Bullous form of systemic lupus erythematosus; Linear IgA dermatoses Pemphigoid
It is a second-line medication for the treatment and prevention of pneumocystis pneumonia and for the prevention of toxoplasmosis in those who have poor immune function
1,2 Treatment of bullous pemphigoid presents a challenge to the clinician, as first-line treatment regimens—either oral corticosteroids or whole body application of super-potent topical steroids—result in substantial morbidity and Bullous pemphigoid (BP) is a subepidermal blistering disease associated with autoantibodies to the hemidesmosomal 180 kD BP autoantigen (BP180)
DH is considered an extraintestinal manifestation of celiac disease (CD)
It can affect the skin only, mucous membranes only, or both the skin and mucous membranes
Oral dosage
Mucous membrane pemphigoid is the designation given to a heterogeneous group of rare chronic autoimmune disorders that tend to cause waxing and waning bullous lesions of the mucous membranes, often with subsequent scarring and morbidity
IV immune globulin has been used occasionally
The anti-inflammatory action of dapsone lies in its ability to suppress neutrophils migration and production of toxic secretory products that cause skin damage Usual Pediatric Dose for Toxoplasmosis - Prophylaxis
The precise mechanism of action of ECP is unknown
e
4 In the previous studies, dapsone has shown promise in treating conjunctival, oral, and laryngeal lesions of mucous The exact mechanism of immunosuppression is not known
1999; 88:159-63 Little is known about the mechanism of dapsone efficacy in antibody-mediated diseases such as linear immunoglobulin A bullous dermatosis (IgA dermatosis) and bullous pemphigoid
Pemphigus diseases are a group of autoimmune blistering diseases of the skin and mucous membranes characterized by intraepithelial cleft and acantholysis
Dapsone (Oral Route) Drug information provided by: Merative, Micromedex
Bullous pemphigoid (BP) is an autoimmune blistering disorder that predominantly affects the elderly
Side effects that usually do not require medical attention (report to your doctor or health care professional if they continue or are bothersome): headache
Other systemic medications were also used in the management of dyshidrosiform bullous pemphigoid patients
06)
It is a white, odorless crystalline powder, practically insoluble in water and in-soluble in fixed and vegetable oils
11-45 clearly de- cacious than dapsone in cicatricial pemphigoid
All but one patient have received oral and/or topical corticosteroids prior to
Initially
Dapsone exerts its anti-bacterial effects by inhibiting dihydrofolic acid synthesis, leading to inhibition of bacterial growth, while its anti-inflammatory properties
In three patients with "intolerance" to sulfapyridine, therapy was changed to dapsone because of nausea, vomiting, headache, or lack of efficacy over a 6-week to 6
Its mechanism of action is probably similar to
The effec-tiveness of dapsone for this indication, however, remains controversial
1177/2050313X241231535
Clinical presentation is similar to standard bullous pemphigoid (BP) but mucous membranes and cephalic lesions are more frequent
9 years, and the average previous treatment failure was 2
Mucous membrane pemphigoid is the designation given to a heterogeneous group of rare chronic autoimmune disorders that tend to cause waxing and waning bullous lesions of the mucous membranes, often with subsequent scarring and morbidity
1,2 Treatment of bullous pemphigoid presents a challenge to the clinician, as first-line treatment regimens—either oral corticosteroids or whole body application of super-potent
The antibiotic dapsone is frequently used to treat both diseases
Inhibition of neutrophil adherence to antibody by dapsone: a possible therapeutic mechanism of dapsone in the treatment of IgA dermatoses
Side effects that usually do not require medical attention (report to your doctor or health care professional if they continue or are bothersome): headache
Abstract
Mechanism: Since dapsone is used for both systemic and dermatologic disease, it has been shown that it possesses multiple different mechanisms
In vivo, it is characterized by linear deposition of IgG, IgA, or C3 along the epithelial basement membrane zone
There is an association with human leukocyte antigen (HLA) indicating a genetic predisposition to the The patient is given a cycle every four weeks
J Am Acad Dermatol
(2) Any novel, safe and effective therapy for BP would be most welcome
8 The 2009 review
06)
These included dapsone (eight individuals whose dose ranged from 50 to 200 mg daily, median 150 mg daily) [4,6 These results imply an important role for IgE in the disease mechanism of bullous pemphigoid, and
Dosage ranges from 1–4 mg/kg/day depending upon the patient's thiopurine methyltransferase level